查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1917824

用於治療睡眠呼吸中止症的居家醫療設備 - 2026-2031 年預測

Home-Based Sleep Apnea Devices Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2025 年，睡眠呼吸中止症居家醫療設備市場規模將達到 23.99 億美元，到 2031 年將達到 56.47 億美元，複合年成長率為 15.34%。

睡眠呼吸中止症居家醫療設備市場涵蓋了用於診斷和治療睡眠相關呼吸障礙（主要是阻塞型睡眠呼吸中止症(OSA)）的醫療設備的研發、生產和銷售，這些設備無需在傳統睡眠檢查室即可使用。此細分市場包含多種技術，從診斷篩檢工具到用於正壓通氣 (PAP) 治療的設備。這些解決方案利用先進的感測器、數據分析和以用戶為中心的設計，為家庭用戶提供了便捷、易用且臨床有效的替代方案，以取代中心多導睡眠圖檢查，從而解決睡眠障礙識別和管理長期護理方面的關鍵挑戰。

市場擴張的根本驅動力在於流行病學、技術和醫療服務趨勢的強大聯合。其中一個關鍵催化劑是全球睡眠呼吸中止症盛行率的不斷上升，而這又受到人口老化、肥胖率上升以及臨床醫生日益認知到睡眠呼吸中止症與心血管疾病、糖尿病和認知障礙之間關聯的推動。病患群體的快速成長對有限的睡眠檢查室資源造成了不永續的需求，因此亟需可擴展的診斷替代方案。同時，遠端醫療和遠端患者監護（RPM）模式的普及，得益於近期醫療服務模式的轉變，為分散式睡眠照護創造了有利環境。這些模式依賴可靠的居家數據收集，居家睡眠呼吸中止症檢測（HSAT）和連網治療設備已成為虛擬護理路徑的重要組成部分。

一項關鍵的技術趨勢是診斷和監測設備正朝著更精密、小型化和使用者友善的方向快速發展。最新的 III 型和 IV 型家用睡眠測試設備將多種感測器（測量氣流、呼吸努力、脈搏血氧計，在某些情況下還能測量打鼾和體位）整合到一種不顯眼的穿戴式設備中。這種向非侵入式、舒適設備的轉變對於提高患者對測試通訊協定的依從性以及確保數據準確性至關重要。此外，透過藍牙或蜂窩網路連接與數位健康平台整合，可實現數據無縫傳輸到雲端門戶，供臨床醫生查看，並有助於實現自動評分演算法。配套應用程式也支持病人參與，從而為治療管理創建持續的回饋循環。

從地理來看，北美是市場最為成熟發達，其特點是疾病認知度高，家庭睡眠呼吸中止症檢測（HSAT）和持續氣道正壓通氣（PAP）的報銷機製完善，且主要設備製造商集中於此。該地區的法規環境和支付方政策歷來對家庭檢測持支持態度，鞏固了其作為創新、臨床檢驗和商業化策略中心的重要地位。

儘管成長要素強勁，但市場在臨床檢驗、報銷和患者依從性方面仍面臨諸多挑戰。確保家用診斷設備的正確使用始終是一個難題。這些設備通常會推薦給患有中重度阻塞性睡眠呼吸中止症（OSA）且無明顯合併症的患者。使用不當可能導致假陰性結果和評估不足。家用檢測和監測的報銷政策仍在不斷發展變化，且因地區而異，這影響著市場進入和商業性可行性。長期患者依從性是整個治療設備產業（尤其是PAP設備）面臨的關鍵挑戰，這推動了設備舒適度（例如面罩設計、壓力釋放技術）和數位指導工具的創新，以提高患者的依從性。

呼吸和睡眠醫學領域的競爭格局主導由全球領先領導企業，它們憑藉包括診斷設備、PAP呼吸器、面罩和數位健康平台在內的全面產品系列競爭。競爭的重點在於感測器精度、數據整合能力和患者介面系統舒適度等方面的技術差異化，以及建構連接患者、醫療服務提供者和支付方的綜合數位生態系統。成功與否取決於能否證明其產品能夠改善患者預後並提高成本效益，貫穿從診斷到長期治療管理的整個醫療服務鏈。

總之，睡眠呼吸中止症居家醫療設備市場是向去中心化、以患者為中心的遠端醫療。對於業內專家而言，策略重點應集中在以下三點：透過提高更簡便設備的診斷準確性來擴大其合理使用範圍；開發無縫連接診斷、治療啟動和依從性支持的整合數位化路徑；以及產生可靠的真實世界證據，以確保獲得有利且穩定的報銷。成功取決於創建端到端的解決方案，這些方案不僅能夠識別疾病，還能有效地引導患者進行長期管理，從而改善臨床結果並減輕未治療睡眠呼吸中止症對整個醫療系統的負擔。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

5. 依設備類型分類的睡眠呼吸中止症居家醫療器材市場

  • 介紹
  • 正壓通氣（PAP）設備
    • 持續正壓呼吸器
    • 自調節正壓呼吸裝置
    • 雙水平正壓呼吸裝置
  • 口內矯正器
  • 其他

6. 依睡眠呼吸中止症類型分類的居家醫療設備市場

  • 介紹
  • 阻塞型睡眠呼吸中止症症（OSA）
  • 中樞性睡眠呼吸中止症（CSA）

7. 按最終用戶分類的睡眠呼吸中止症居家醫療器材市場

  • 介紹
  • 兒童（18歲以下）
  • 成年人（18-65歲）
  • 老年人（65歲以上）

8. 各地區睡眠呼吸中止症居家醫療器材市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章：競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第10章：公司簡介

  • ResMed Inc.
  • Koninklijke Philips NV
  • Fisher & Paykel Healthcare Limited
  • Drive DeVilbiss Healthcare
  • BMC Medical Co., Ltd
  • Compumedics Limited
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • SomnoMed Limited
  • Somnetics, International Inc.

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061615809

Home-Based Sleep Apnea Devices Market, with a 15.34% CAGR, is expected to grow to USD 5.647 billion in 2031 from USD 2.399 billion in 2025.

The home-based sleep apnea devices market encompasses the development, manufacturing, and distribution of medical devices designed for the diagnosis and management of sleep-related breathing disorders, primarily obstructive sleep apnea (OSA), outside of traditional sleep laboratories. This market segment includes a spectrum of technologies ranging from diagnostic screening tools to therapeutic devices for positive airway pressure (PAP) therapy. These solutions leverage advanced sensors, data analytics, and user-centric design to provide accessible, convenient, and clinically valid alternatives to in-lab polysomnography, addressing critical gaps in sleep disorder identification and long-term care management.

Market expansion is fundamentally driven by a powerful confluence of epidemiological, technological, and healthcare delivery trends. The primary catalyst is the globally rising prevalence of sleep apnea, fueled by aging demographics, increasing rates of obesity, and greater clinical recognition of the condition's association with cardiovascular disease, diabetes, and cognitive impairment. This burgeoning patient population creates an unsustainable demand for limited sleep lab resources, necessitating scalable diagnostic alternatives. Concurrently, the accelerated adoption of telemedicine and remote patient monitoring (RPM) models, accelerated by recent shifts in healthcare delivery, has created a receptive ecosystem for decentralized sleep care. These models rely on reliable home-based data collection, making home sleep apnea tests (HSATs) and connected therapeutic devices integral components of virtual care pathways.

A dominant technological trend is the rapid evolution of diagnostic and monitoring devices toward greater sophistication, miniaturization, and user-friendliness. Modern Type III and IV home sleep tests incorporate multi-parameter sensors-measuring airflow, respiratory effort, pulse oximetry, and sometimes snoring or body position-packaged into unobtrusive, wearable formats. This shift towards non-intrusive, comfortable devices is critical for improving patient compliance with testing protocols and ensuring data accuracy. Furthermore, integration with digital health platforms via Bluetooth or cellular connectivity enables seamless data transmission to cloud-based portals for clinician review, facilitates automated scoring algorithms, and supports patient engagement through companion apps, creating a continuous feedback loop for therapy management.

Geographically, North America remains the most mature and advanced market, characterized by high disease awareness, established reimbursement frameworks for HSATs and PAP therapy, and a concentration of leading device manufacturers. The region's regulatory environment and payer policies have historically been more adaptive to home-based testing, solidifying its role as the primary center for innovation, clinical validation, and commercial strategy.

Despite strong growth drivers, the market navigates significant challenges related to clinical validation, reimbursement, and patient adherence. A persistent challenge is ensuring the appropriate use of home-based diagnostic devices, which are generally recommended for patients with a high pre-test probability of moderate to severe OSA and without significant comorbidities. Misapplication can lead to false negatives or inadequate assessment. Reimbursement policies for home-based testing and monitoring continue to evolve and vary by region, impacting market access and commercial viability. For therapeutic devices, particularly PAP machines, long-term patient adherence remains a critical industry-wide hurdle, driving innovation in device comfort (e.g., mask design, pressure relief technology) and digital coaching tools to improve compliance.

The competitive landscape is dominated by established global leaders in respiratory and sleep medicine, who compete across a full portfolio of diagnostic devices, PAP machines, masks, and digital health platforms. Competition centers on technological differentiation in sensor accuracy, data integration capabilities, patient interface comfort, and the development of comprehensive digital ecosystems that connect patients, providers, and payers. Success hinges on demonstrating improved patient outcomes and cost-effectiveness across the care continuum, from diagnosis to long-term therapy management.

In conclusion, the home-based sleep apnea devices market is a dynamic and essential component of the shift towards decentralized, patient-centric healthcare. Its growth is structurally supported by the high and growing burden of sleep apnea and the irreversible trend toward telehealth. For industry experts, strategic focus must center on advancing the diagnostic accuracy of simpler devices to expand their appropriate use, developing integrated digital pathways that seamlessly connect diagnosis with treatment initiation and adherence support, and generating robust real-world evidence to secure favorable and stable reimbursement. Success depends on creating end-to-end solutions that not only identify the disease but also effectively engage patients in long-term management, thereby improving clinical outcomes and reducing the overall systemic burden of untreated sleep apnea.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Home-Based Sleep Apnea Market Segmentation

  • By Device Type
  • Positive Airway Pressure (PAP) Device
  • Continuous Positive Airway Pressure Device
  • Auto-Adjusting Positive Airway Pressure Device
  • Bilevel Positive Airway Pressure Device
  • Oral Appliance
  • Others
  • By Sleep Apnea Type
  • Obstructive Sleep Apnea (OSA)
  • Central Sleep Apnea (CSA)
  • By End-User
  • Pediatric (Under 18 Years)
  • Adults (18 To 65 Years)
  • Old-Age (Above 65 Years)
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HOME-BASED SLEEP APNEA MARKET BY DEVICE TYPE

  • 5.1. Introduction
  • 5.2. Positive Airway Pressure (PAP) Device
    • 5.2.1. Continuous Positive Airway Pressure Device
    • 5.2.2. Auto-Adjusting Positive Airway Pressure Device
    • 5.2.3. Bilevel Positive Airway Pressure Device
  • 5.3. Oral Appliance
  • 5.4. Others

6. HOME-BASED SLEEP APNEA MARKET BY SLEEP APNEA TYPE

  • 6.1. Introduction
  • 6.2. Obstructive Sleep Apnea (OSA)
  • 6.3. Central Sleep Apnea (CSA)

7. HOME-BASED SLEEP APNEA MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pediatric (Under 18 Years)
  • 7.3. Adults (18 To 65 Years)
  • 7.4. Old-Age (Above 65 Years)

8. HOME-BASED SLEEP APNEA MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. ResMed Inc.
  • 10.2. Koninklijke Philips N.V
  • 10.3. Fisher & Paykel Healthcare Limited
  • 10.4. Drive DeVilbiss Healthcare
  • 10.5. BMC Medical Co., Ltd
  • 10.6. Compumedics Limited
  • 10.7. Natus Medical Incorporated
  • 10.8. Nihon Kohden Corporation
  • 10.9. SomnoMed Limited
  • 10.10. Somnetics, International Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations